Clinical Trials Sponsored by Eisai Deutschland

Total 891 results

Eisai Co., Ltd.

Completed

Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.

End-Stage Renal Disease

Japan
Eisai Co., Ltd.

Completed

A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome

Acute Coronary Syndrome

Japan
Eisai Co., Ltd.

Completed

Study of E3810 for Healthy Japanese Male (Under Fasting Condition)

Healthy
Eisai Co., Ltd.

Completed

A Bioequivalence and Food Effect Study of SEP-190 in Japanese Healthy Subjects (Study SEP 190-102)

Insomnia

Japan
Eisai Co., Ltd.

Completed

An add-on Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-epileptic Drugs (AEDs)

Refractory Partial Seizures

Japan
Eisai Co., Ltd.

Completed

A Clinical Trial to Study the Effects of a Fixed Dose Combination of Diclofenac and Eperisone Hydrochloride With Plain Eperisone Hydrochloride in Patients With Low Back Pain

Acute Musculoskeletal Spasm Due to Low Back Pain

India
Eisai Co., Ltd.

Completed

A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)

Healthy

Japan
Eisai China Inc.

Completed

Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China

Lumbar Disc Degenerative Disease

China
Eisai Korea Inc.

Completed

A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies

Epilepsy

Korea, Republic of
Hologic Deutschland GmbH
University Hospital Tuebingen

Completed

Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens

Human Papilloma Virus Infection
Universitätsklinikum Hamburg-Eppendorf
Olympus Deutschland GmbH

Completed

How Effective Can a Simulator-Based Training Course For Beginners In Endoscopy Be Made? (EFFEKTRA)

Physicians Gastroscopy Training

Germany
Servier Deutschland GmbH
iOMEDICO AG

Completed

Trifluridin/tipirACil in meTastatIc Colorectal Cancer (TACTIC)

Metastatic Colorectal Cancer

Germany
Eisai Inc.

Recruiting

A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease

Alzheimer Disease

United States, United Kingdom
Eisai Inc.

Available

An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303

Lennox Gastaut Syndrome

Poland
Eisai Inc.

Completed

A Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Participants With Moderate to Severe Obstructive Sleep Apnea, and in Adult and Elderly Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease

Sleep Apnea, Obstructive | Respiration Disorders | Pulmonary Disease, Chronic Obstructive

United States
Eisai Inc.

Completed

Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Endometrial Cancer

United States, Poland, Ukraine, Bulgaria, Romania, Belgium, Russian Federation, Hungary
Eisai Inc.

Completed

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Locally Recurrent | Metastatic Breast Cancer ( HER2 Negative)

United States
Eisai Inc.

Completed

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Soft Tissue Sarcoma

United States, France, United Kingdom, Germany, Spain, Belgium, Argentina, Israel, Poland, Romania, Korea, Republic of, Canada, Netherlands, Australia, New Zealand, Singapore, Brazil, Russian Federation, Austria, Thailand, Italy, ... and more
Eisai Inc.

Completed

A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Taiwan, Hong Kong, Spain, Poland, Singapore, Russian Federation, Italy, Australia, France, Germany, Japan, United Kingdom, Korea, Republic of
Eisai Inc.

Completed

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
Eisai Inc.

Completed

A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)

Partial Onset Seizures

Germany, Sweden, Norway, Austria, Denmark
Eisai Inc.

Completed

Dose-Finding Study of E7070 in Combination With Irinotecan

Cancer

United States
Eisai Inc.

Completed

A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants

Healthy Volunteers

United States
Eisai Inc.

Terminated

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Pediatric Acute Myelogenous Leukemia (AML)

United States, Canada, Australia
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

Partial Onset Seizures | Primary Generalized Tonic-Clonic Seizures | Secondarily Generalized Seizures

United States
Eisai Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years

Obesity

United States
Eisai Inc.

Terminated

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Advanced Solid Tumors

United States
Eisai Inc.

Completed

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

United States
Eisai Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

Alzheimer's Disease

United States
Eisai Inc.

Completed

A Study to Determine the Signs and Symptoms That Impact Daily Life of Participants With Irregular Sleep-Wake Rhythm Disorder

Irregular Sleep Wake Rhythm Disorder

United States
Eisai Inc.

Completed

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

Insomnia Disorder

United States, Canada, Finland, Germany, Italy, Japan, Korea, Republic of, Mexico, New Zealand, Poland, Romania, Spain
Eisai Inc.

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia

Elderly | Chronic Insomnia | Adults

United States
Eisai Inc.

Completed

Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder

Insomnia Disorder

United States
Eisai Inc.

Terminated

A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Thyroid Carcinoma, Anaplastic

Italy, United States, France, Australia, United Kingdom
Eisai Inc.

Completed

BLOSSOM: Behavioral Modification and Lorcaserin Second Study for Obesity Management

Obesity

United States
Eisai Inc.

Completed

Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age

Pharmacokinetics in Obese Adolescents

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment

Renal Impairment

United States
Eisai Inc.

Completed

Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

Obesity

United States
Eisai Inc.

Completed

Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung

KIF5B-RET-Positive Adenocarcinoma of the Lung

United States, Hong Kong, Japan, Taiwan, Singapore
Eisai Inc.

Completed

Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

Healthy Volunteers

United States
Eisai Inc.

Completed

Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers

Healthy Volunteers

United States
Eisai Inc.

Approved for marketing

Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil

Thyroid Cancer

Brazil
Eisai Inc.

Completed

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

Healthy Participants

United States
Eisai Inc.

Terminated

Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT

Parkinson's Disease

United States
Eisai Inc.

Completed

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Idiopathic Thrombocytopenic Purpura

United States
Eisai Inc.

Completed

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

Thrombocytopenia Associated With Liver Disease

United States, China, Spain, Argentina, Belgium, Israel, Mexico, Romania, Japan, Brazil, Russian Federation, Germany, Italy, Czechia, Canada, Australia, France
Eisai Inc.

Completed

A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors

Advanced Colorectal Cancer

United States, Canada
Eisai Inc.

Completed

A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures

Seizure Disorder Generalized Tonic Clonic
Eisai Inc.

Completed

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

Severe Sepsis

United States, France, Poland, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Switzerland, Argentina, Belgium, Israel, South Africa, Japan, Canada, Netherlands, Korea, Republic of, Australia, Chile, Brazil, Austria, Italy, Czechia, Portug...
Eisai Inc.

Completed

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Early Alzheimer's Disease

United States

3

Subscribe